Cancer grading gets an upgrade

by Rosie Hales
Cancer grading gets an upgrade
A microscope view of prostate cancer. Credit: David M. Berman, 2014.

(Medical Xpress)—Prostate cancer is the second most commonly diagnosed cancer among Canadian men but only about half of these cancers grow rapidly enough to require treatment.

However, determining which prostate cancers need to be treated can be tricky because it's hard to predict through biopsy which cancers will eventually become harmful. In fact, because biopsies often do not yield accurate information, between a third and half of patients initially diagnosed with harmless prostate cancers are likely to be "upgraded" to potentially harmful cancers within a year or two of diagnosis.

A research team led by Dr. David Berman, a professor in the Department of Pathology and Molecular Medicine at Queen's, and Dr. Tamara Lotan from Johns Hopkins University discovered that the decline of a specific protein within a tumour could help identify the tumours requiring treatment.

"We have shown that a tumour-suppressing protein called phosphatase and tensin homolog, or PTEN, is lost most frequently in prostate tumours that will become harmful and require treatment," says Dr. Berman. "The team from Johns Hopkins has done a terrific job of making this test more reliable and valid and applicable to prostate cancer and to other forms of cancer."Currently, the Gleason Grading system is used to determine the harmful potential of prostate cancers. Scores usually range from 6 to 10, with lower numbers often indicating cancers that are unlikely to become harmful.

One hundred and seventy four patients with a Gleason score of 6 had The team measured PTEN levels in cancers biopsied from 174 patients, who appeared to have harmless cancers with Gleason scores of 6 or less. Seventy-one of these cases were upgraded to potentially harmful cancers with a score of 7 after the entire was surgically removed and examined by pathologists. Importantly, PTEN loss found in biopsies helped separate harmless cancers from their more dangerous look-alikes.

"The 71 patients who had their tumours upgraded had a three times higher rate of PTEN loss than the group that was accurately graded," says Dr. Berman. "Although the percentage of who have PTEN loss is low, this finding is extremely exciting as it proves that measuring proteins in biopsies can improve accuracy. Also, it's a fairly simple test that could be done in any pathology lab."

add to favorites email to friend print save as pdf

Related Stories

Prostate cancer biomarkers identified in seminal fluid

Jun 06, 2014

(Medical Xpress)—Improved diagnosis and management of one of the most common cancers in men - prostate cancer - could result from research at the University of Adelaide, which has discovered that seminal ...

Recommended for you

Researcher to cancer: 'Resistance will be futile'

1 hour ago

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease. "Cancer cells rapidly ...

How does prostate cancer form?

3 hours ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

Low risk of malignancy for small complex adnexal masses

10 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.